Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4mg, for intracanalicular use, has completed Phase 3 clinical development for post-surgical ocular inflammation and pain. DEXTENZA is also in Phase 3 clinical development for allergic conjunctivitis. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. The company’s first commercial product, the ReSure® Sealant, is the first and only sealant that has been approved by the Food and Drug Administration (FDA) for ophthalmic use.
Aspiring to be a leader in ophthalmology by leveraging its proven hydrogel platform technology to innovate elegant drug product solutions that improve outcomes in ocular diseases and enhance patient and provider experience.